The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HLA-B*57:01 is associated with flucloxacillin-induced DILI.
“HLA-B*57:01 is associated with flucloxacillin, HLA-B*35:02 with minocycline, and HLA-A*33:01 with terbinafine.”
From Drug-induced liver injury. Part I: Classification, diagnosis and treatment (2025) · cites this paper as [30]
Several genetic studies have identified distinct HLA alleles as risk factors for specific drugs.
“Several genetic studies have also identified distinct human leukocyte antigen (HLA) alleles as risk factors for specific drugs.”
From Drug-induced liver injury. Part I: Classification, diagnosis and treatment (2025) · cites this paper as [30]
HLA-A*33:01 is associated with terbinafine-induced DILI.
“HLA-B*57:01 is associated with flucloxacillin, HLA-B*35:02 with minocycline, and HLA-A*33:01 with terbinafine.”
From Drug-induced liver injury. Part I: Classification, diagnosis and treatment (2025) · cites this paper as [30]
HLA-B*35:02 is associated with minocycline-induced DILI.
“HLA-B*57:01 is associated with flucloxacillin, HLA-B*35:02 with minocycline, and HLA-A*33:01 with terbinafine.”
From Drug-induced liver injury. Part I: Classification, diagnosis and treatment (2025) · cites this paper as [30]
Pretreatment HLA testing will likely not prove useful in most circumstances to prevent DILI, but HLA testing may be helpful in DILI diagnosis and causality assessment.
“Therefore, pretreatment HLA testing will likely not prove useful in most circumstances to prevent DILI, but HLA testing may be helpful in DILI diagnosis and causality assessment [29-32].”
From Drug-induced liver injury. Part I: Classification, diagnosis and treatment (2025) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Self-citationGenes mirror geography within Europe
Novembre, J., Johnson, T., Bryc, K., Kutalik, Z., Boyko, A. R., Auton, A., Indap, A., King, K. S., Bergmann, S., Nelson, M. R., et al. (2008) · Nature · doi:10.1038/nature07331 · Cited by 1,479
Self-citationIdiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Rare Variants Create Synthetic Genome-Wide Associations
Dickson, S. P., Wang, K., Krantz, I., Hakonarson, H., & Goldstein, D. B. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000294 · Cited by 857
Self-citationde Bakker, P. I. W., McVean, G., Sabeti, P. C., Miretti, M. M., Green, T., Marchini, J., Ke, X., Monsuur, A. J., Whittaker, P., Delgado, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1885 · Cited by 766
Self-citationNelson, M. R., Bryc, K., King, K. S., Indap, A., Boyko, A. R., Novembre, J., Briley, L. P., Maruyama, Y., Waterworth, D. M., Waeber, G., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.08.005 · Cited by 293
Self-citation
Flagged first, then by citations
Research works printed but not linked: 30
- Sgro, 2002, Incidence of drug-induced hepatic injuries: a French population-based study, Hepatology, 36, 451, 10.1053/jhep.2002.34857 · DOI · Paper page
- Ostapowicz, 2002, Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States, Ann Intern Med, 137, 947, 10.7326/0003-4819-137-12-200212170-00007 · DOI · Paper page
- Stricker, 1989, Cholestatic hepatitis due to antibacterial combination of amoxicillin and clavulanic acid (augmentin), Dig Dis Sci, 34, 1576, 10.1007/BF01537113 · DOI
- de Abajo, 2004, Acute and clinically relevant drug-induced liver injury: a population based case-control study, Br J Clin Pharmacol, 58, 71, 10.1111/j.1365-2125.2004.02133.x · DOI
- Andrade, 2005, Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period, Gastroenterology, 129, 512, 10.1016/j.gastro.2005.05.006 · DOI · Paper page
- Chalasani, 2008, Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States, Gastroenterology, 135, 1924, 10.1053/j.gastro.2008.09.011 · DOI · Paper page
- Andrade, 2006, Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry, Hepatology, 44, 1581, 10.1002/hep.21424 · DOI · Paper page
- Garcia Rodriguez, 1996, Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid, Arch Intern Med, 156, 1327, 10.1001/archinte.1996.00440110099013 · DOI
- Fontana, 2005, Acute liver failure due to amoxicillin and amoxicillin/clavulanate, Dig Dis Sci, 50, 1785, 10.1007/s10620-005-2938-5 · DOI
- Hautekeete, 1999, HLA association of amoxicillin-clavulanate-induced hepatitis, Gastroenterology, 117, 1181, 10.1016/S0016-5085(99)70404-X · DOI
- O'Donohue, 2000, Co-amoxiclav jaundice: clinical and histological features and HLA class II association, Gut, 47, 717, 10.1136/gut.47.5.717 · DOI
- Donaldson, 2010, Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury, J Hepatol, 53, 1049, 10.1016/j.jhep.2010.05.033 · DOI
- Andrade, 2004, HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease, Hepatology, 39, 1603, 10.1002/hep.20215 · DOI
- Lucena, 2006, Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain, Hepatology, 44, 850, 10.1002/hep.21324 · DOI
- Daly, 2009, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat Genet, 41, 816, 10.1038/ng.379 · DOI
- Molokhia, 2006, EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions, Pharmacogenomics, 7, 633, 10.2217/14622416.7.4.633 · DOI
- Fontana, 2009, Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct, Drug Saf, 32, 55, 10.2165/00002018-200932010-00005 · DOI · Paper page
- Danan, 1993, Causality assessment of adverse reactions to drugs, J Clin Epidemiol, 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
- Browning, 2007, Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering, Am J Hum Genet, 81, 1084, 10.1086/521987 · DOI
- Ahmadi, 2005, A single-nucleotide polymorphism tagging set for human drug metabolism and transport, Nat Genet, 37, 84, 10.1038/ng1488 · DOI
- Chung, 2007, PTPN22: its role in SLE and autoimmunity, Autoimmunity, 40, 582, 10.1080/08916930701510848 · DOI
- Kaniwa, 2008, HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis, Pharmacogenomics, 9, 1617, 10.2217/14622416.9.11.1617 · DOI
- Moore, 2009, Epistasis and its implications for personal genetics, Am J Hum Genet, 85, 309, 10.1016/j.ajhg.2009.08.006 · DOI
- Hirschfield, 2009, Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants, N Engl J Med, 360, 2544, 10.1056/NEJMoa0810440 · DOI · Paper page
- Selmi, 2009, The role of environmental factors in primary biliary cirrhosis, Trends Immunol, 30, 415, 10.1016/j.it.2009.05.006 · DOI
- Singer, 2010, A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury, Nat Genet, 42, 711, 10.1038/ng.632 · DOI
- Kindmark, 2008, Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis, Pharmacogenomics J, 8, 186, 10.1038/sj.tpj.6500458 · DOI
- Spraggs, 2011, HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer, J Clin Oncol, 29, 667, 10.1200/JCO.2010.31.3197 · DOI
- Hirata, 2008, Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study, Pharmacogenomics J, 8, 29, 10.1038/sj.tpj.6500442 · DOI
- Ashley, 2010, Clinical assessment incorporating a personal genome, Lancet, 375, 1525, 10.1016/S0140-6736(10)60452-7 · DOI · Paper page
Cited by
Sorted by citations
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Self-citationStravitz, R. T., & Lee, W. M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31894-x · Cited by 844
Drug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network
Navarro, V. J., Barnhart, H., Bonkovsky, H. L., Davern, T., Fontana, R. J., Grant, L., Reddy, R. K., Seeff, L. B., Serrano, J., Sherker, A. H., et al. (2014) · Hepatology · doi:10.1002/hep.27317 · Cited by 418
Self-citationAASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Self-citationMechanisms of drug-induced liver injury
Yuan, L., & Kaplowitz, N. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.07.002 · Cited by 322
Central role of mitochondria in drug-induced liver injury
Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.604086 · Cited by 277
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S. M., Hamid, S., Tan, S. S., Philips, C. A., George, J., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10144-3 · Cited by 181
Self-citationGenetics of primary sclerosing cholangitis and pathophysiological implications
Jiang, X., & Karlsen, T. H. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.154 · Cited by 155
Li, Y., Phillips, E. J., Dellinger, A., Nicoletti, P., Schutte, R., Li, D., Ostrov, D. A., Fontana, R. J., Watkins, P. B., Stolz, A., et al. (2021) · Hepatology · doi:10.1002/hep.31258 · Cited by 76
Self-citationInagaki, K., Mori, N., Honda, Y., Takaki, S., Tsuji, K., & Chayama, K. (2017) · Kanzo · doi:10.2957/kanzo.58.448 · Cited by 35
What have we learned from animal models of idiosyncratic, drug-induced liver injury?
Roth, R. A., & Ganey, P. E. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1760246 · Cited by 8
The contemporary epidemiology, causes, and management of drug-induced liver injury
Swanson, L., & Fontana, R. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001011
Self-citation
Metadata
- Authors
- Lucena, M. I., Molokhia, M., Shen, Y., Urban, T. J., Aithal, G. P., Andrade, R. J., Day, C. P., Ruiz–Cabello, F., Donaldson, P. T., Stephens, C., Pirmohamed, M., Romero–Gomez, M., Navarro, J. M., Fontana, R. J., Miller, M., Groome, M., Bondon–Guitton, E., Conforti, A., Stricker, B. H. C., Carvajal, A., Ibanez, L., Yue, Q., Eichelbaum, M., Floratos, A., Pe'er, I., Daly, M. J., Goldstein, D. B., Dillon, J. F., Nelson, M. R., Watkins, P. B., & Daly, A. K.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 141
- Issue
- 1
- Pages
- 338-347
- ISSN
- 0016-5085
- PMC
- PMC3129430
- Cited by
- 442
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review